相关实验视频
Updated: Jan 6, 2026

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
2.0K
在患有轻度认知障碍的帕金森病时进行认知刺激
Jolanda Buonocore1,2, Noemi Iaccino1, Giusi Torchia1
1Institute of Neurology, Department of Medical and Surgical Sciences, University "Magna Graecia", 88100, Catanzaro, Italy.
Journal of neurology
|September 27, 2025
概括
远程康复有效地改善了帕金森病轻度认知障碍 (PD-MCI) 的认知功能. 患者在干预后六个月内表现出对记忆和执行功能的持久益处.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 数字健康数字健康
背景情况:
- 认知障碍是帕金森病 (PD) 的常见和致残的非运动症状,严重影响患者的自主性和生活质量.
- 认知刺激 (CS) 已被公认为用于神经退行性疾病,但其在PD中的有效性需要进一步研究.
- 这项研究比较了基于虚拟现实,在家提供的CS程序与PD患者的传统面对面的CS.
研究的目的:
- 用虚拟现实康复系统 (VRRS) 来评估由治疗师指导的家庭CS计划的有效性.
- 为了比较VRRS提供的CS干预与PD和轻度认知障碍 (PD-MCI) 患者的传统面对面的CS计划.
主要方法:
- 45名患有PD-MCI的患者随机分配到远程康复组 (TRG,n=25) 或对照组 (CG,n=20).
- 两组都接受了标准化的4周多领域的CS课程 (20次/周).
- TRG参与者通过VRRS与远程监督在家接受培训;CG参与者接受了面对面的门诊治疗. 认知和临床结果在基线,干预后和6个月后期被评估.
主要成果:
- 在两组中都观察到高守率 (>90%).
- 与干预后的CG相比,TRG在全球认知,工作记忆和延迟回忆方面表现出明显的改善.
- 在TRG中,这些认知益处在6个月的随访中保持不变,特别是对于记忆和执行功能,即使在进行统计调整后也是如此.
结论:
- 通过远程康复提供的短期,由治疗师指导的CS计划有效地提高了PD-MCI患者的认知功能.
- 基于VRRS的干预措施显示了持续的好处,特别是在记忆和执行领域,强调远程医疗是帕金森病认知护理的可行和可访问的方法.
- 这项研究支持使用远程康复系统为PD患者提供认知干预,改善可访问性并可能提高生活质量.
相关概念视频
Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
496
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
496
Cognitive Development During Adulthood
737
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
737
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K

